Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
109last 24h
3129last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
Simply Wall St.40d agoneutral
Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug24/7 Wall St.40d agoneutral
Prediction: Eli Lilly’s Next Growth Wave Could Surprise InvestorsInvesting.com40d agoneutral
Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug dealInsider Monkey41d agoneutral
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?Insider Monkey41d agobullish
Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?Benzinga Private Markets41d agobullish
Anthropic Claude’s Claimed Breakthrough in Biology Faces a Major Question - Scientist Says He Had Already Studied the Enzymes for 4 Years24/7 Wall St.41d agoneutral
Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to ComeInsider Monkey42d agoneutral
Can Novo Nordisk (NVO) Find a Second Act Before its First One Fades?Motley Fool42d agobullish
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?Simply Wall St.43d agoneutral
What Is Novo Nordisk (CPSE:NOVO B) Getting From A €1.165 Billion Licensing Deal?Motley Fool43d agoneutral
Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become